Condition
Serous Ovarian Cancer
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Recruiting1
Unknown1
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT05113368Phase 2Recruiting
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
NCT05057715Phase 1Active Not Recruiting
huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
NCT06055348Phase 1UnknownPrimary
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
Showing all 3 trials